Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 10, 2011, Pages 1591-1603

  Markou, Athina ^a   Liang, Yu ^b   Lianidou, Evi ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Life Technologies Corporation   (United States)

Author keywords

diagnosis; microRNAs; non small cell lung cancer; prognosis; tumor biomarkers

Indexed keywords

BEVACIZUMAB; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; ERLOTINIB; GEFITINIB; MICRORNA; MICRORNA 125A; MICRORNA 126; MICRORNA 132; MICRORNA 152; MICRORNA 154; MICRORNA 17 5P; MICRORNA 17 92; MICRORNA 182; MICRORNA 191; MICRORNA 192; MICRORNA 206; MICRORNA 21; MICRORNA 210; MICRORNA 221; MICRORNA 222; MICRORNA 29; MICRORNA 34; MICRORNA 372; MICRORNA 451; MICRORNA LET 7; PEMETREXED; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INHIBITION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CELL FUNCTION; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; DISEASE MARKER; DNA METHYLATION; DOWN REGULATION; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCUS; GENE REPRESSION; GENE TARGETING; HISTOPATHOLOGY; HUMAN; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NUCLEUS ACCUMBENS; ONCOGENE; OUTCOME ASSESSMENT; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; RETINOBLASTOMA; REVIEW; RISK ASSESSMENT; RNA TRANSCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MICRORNAS; PROGNOSIS;

EID: 80054963718     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.661     Document Type: Review

References (129)

1. American Cancer Society. Cancer facts and figures 2010. http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113. pdf 2010.
2. Feinstein AR, Gelfman NA, Yesner R. Observer variability in the histopathologic diagnosis of lung cancer. Am Rev Respir Dis 1970;101:671-84.
3. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:191-202.
4. Clegg A, Scott DA, Hewitson P, Sidhu M, Waugh N. Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: A systematic review. Thorax 2002;57:20-8. (Pubitemid 34081539)
5. Okamoto T, Maruyama R, Suemitsu R, Aoki Y, Wataya H, Kojo M, et al. Prognostic value of the histological subtype in completely resected non-small cell lung cancer. Interact Cardiovasc Thorac Surg 2006;5:362-6. (Pubitemid 44166436)
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-smallcell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. (Pubitemid 38637993)
7. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. (Pubitemid 38720929)
8. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362: 2380-8.
9. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: A decade of progress. Chest 2002; 122:1037-57.
10. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-8.
11. Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009;10:1001-10.
12. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009;219:214-21.
13. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
14. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993;75:843-54. (Pubitemid 24014542)
15. Tang G, Reinhart BJ, Bartel DP, Zamore PD. A biochemical framework for RNA silencing in plants. Genes Dev 2003;17: 49-63. (Pubitemid 36062508)
16. Bagga S, Bracht J, Hunter S, Massirer K, Holtz J, Eachus R, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 2005;122:553-63. (Pubitemid 41191154)
17. Griffiths-Jones S. miRBase: MicroRNA sequences and annotation. Curr Protoc Bioinformatics, Chapter 12, Unit 12 19 11-10, John Wiley and Sons, March 2010.
18. Bartel DP, Chen CZ. Micromanagers of gene expression: The potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004;5:396-400. (Pubitemid 38529411)
19. Lund E, Guttinger S, Calado A, Dahlberg JE, Kutay U. Nuclear export of microRNA precursors. Science 2004;303:95-8. (Pubitemid 38055779)
20. Chang S, Johnston RJ, Frokjaer-Jensen C, Lockery S, Hobert O. MicroRNAs act sequentially and asymmetrically to control chemosensory laterality in the nematode. Nature 2004;430: 785-9. (Pubitemid 39071349)
21. Johnston RJ, Hobert O. A microRNA controlling left/right neuronal asymmetry in Caenorhabditis elegans. Nature 2003;426: 845-9. (Pubitemid 38056870)
22. Poy, MN, Eliasson, L., Krutzfeldt, J, Kuwajima, S, Ma, X, Macdonald, PE, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004;432:226-30. (Pubitemid 39545853)
23. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005;436:214-20. (Pubitemid 41021266)
24. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-6. (Pubitemid 38055775)
25. Giraldez AJ, Cinalli RM, Glasner ME, Enright AJ, Thomson JM, Baskerville S, et al. MicroRNAs regulate brain morphogenesis in zebrafish. Science 2005;308:833-8. (Pubitemid 40629259)
26. Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW, Ruohola-Baker H. Stem cell division is regulated by the microRNA pathway. Nature 2005;435:974-8. (Pubitemid 40896325)
27. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network-another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007;7:819-22. (Pubitemid 350006254)
28. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
29. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66. (Pubitemid 44629897)
30. Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006;16:4-9. (Pubitemid 43089605)
31. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9. (Pubitemid 35403967)
32. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32. (Pubitemid 41541436)
33. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 2007;26:745-52. (Pubitemid 46856245)
34. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103: 2257-61. (Pubitemid 43271657)
35. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47. (Pubitemid 40343076)
36. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-38. (Pubitemid 40839735)
37. Wang, W, Peng, B, Wang, D, Ma, X, Jiang, D, Zhao, J, et al. Human tumor MicroRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer 2010. wEpub ahead of print.x
38. Tellez CS, Juri DE, Do K, Bernauer AM, Thomas CL, Damiani LA, et al. EMT and stem cell-like properties associated with miR-205 and miR-200 epigenetic silencing are early manifestations during carcinogen-induced transformation of human lung epithelial cells. Cancer Res 2011;71:3087-97.
39. Melo SA, Esteller M. A precursor microRNA in a cancer cell nucleus: Get me out of here! Cell Cycle 2011;10:922-5.
40. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004. (Pubitemid 38327724)
41. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6. (Pubitemid 38697282)
42. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98. (Pubitemid 43357945)
43. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007;67:9762-70. (Pubitemid 47621223)
44. Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 2007;21:1025-30. (Pubitemid 46686471)
45. Johnson, CD, Esquela-Kerscher, A, Stefani, G, Byrom, M, Kelnar, K, Ovcharenko, D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 2007; 67:7713-22. (Pubitemid 47281364)
46. Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 2008;68:8535-40.
47. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57. (Pubitemid 350309743)
48. Brueckner B, Stresemann C, Kuner R, Mund C, Musch T, Meister M, et al. The human let-7a-3 locus contains an epigenetically regulated microRNA gene with oncogenic function. Cancer Res 2007;67:1419-23. (Pubitemid 46383365)
49. Ebi H, Sato T, Sugito N, Hosono Y, Yatabe Y, Matsuyama Y, et al. Counterbalance between RB inactivation and miR-17-92 overexpression in reactive oxygen species and DNA damage induction in lung cancers. Oncogene 2009;28:3371-9.
50. Suarez Y, Fernandez-Hernando C, Yu J, Gerber SA, Harrison KD, Pober JS, et al. Dicer-dependent endothelial microRNAs are necessary for postnatal angiogenesis. Proc Natl Acad Sci USA 2008;105:14082-7.
51. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008;132:875-86. (Pubitemid 351312807)
52. Fish JE, Santoro MM, Morton SU, Yu S, Yeh RF, Wythe JD, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272-84.
53. Liu B, Peng XC, Zheng XL, Wang J, Qin YW. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 2009;66: 169-75.
54. Barshack I, Lithwick-Yanai G, Afek A, Rosenblatt K, Tabibian-Keissar H, Zepeniuk M, et al. MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Pract 2010;206:578-84.
55. Wang X, Ling C, Bai Y, Zhao J. MicroRNA-206 Is associated with invasion and metastasis of lung cancer. Anat Rec (Hoboken) 2011;294:88-92.
56. Jiang L, Huang Q, Zhang S, Zhang Q, Chang J, Qiu X, et al. Hsa-miR-125a-3p and hsa-miR-125a-5p are downregulated in non-small cell lung cancer and have inverse effects on invasion and migration of lung cancer cells. BMC Cancer 2010;10:318.
57. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007;104:15805-10. (Pubitemid 350035380)
58. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005;65:6029-33. (Pubitemid 40994386)
59. Zhu S, Wu H, Wu F, Nie D, Sheng S, Mo YY. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008;18:350-9. (Pubitemid 351333899)
60. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou, M, Georgoulias V, Lianidou ES. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008;54: 1696-704.
61. Zhang JG, Wang JJ, Zhao F, Liu Q, Jiang K, Yang GH. MicroRNA-21 (miR-21) represses tumor suppressor PTEN and promotes growth and invasion in non-small cell lung cancer (NSCLC). Clin Chim Acta 2010;411:846-52.
62. Seike, M, Goto, A, Okano, T, Bowman, ED, Schetter, AJ, Horikawa, I, et al. MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 2009;106:12085-12090.
63. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 2010;70:8822-31.
64. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 2008;68:3566-72.
65. Hatley ME, Patrick DM, Garcia MR, Richardson JA, Bassel-Duby R, van Rooij E, et al. Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. Cancer Cell 2010;18: 282-93.
66. Saito M, Schetter AJ, Mollerup S, Kohno T, Skaug V, Bowman ED, et al. The association of microRNA expression with prognosis and progression in early stage, non small cell lung adenocarcinoma: A retrospective analysis of three cohorts. Clin Cancer Res 2011;17:1875-82.
67. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010;17:193-9.
68. Yan D, Zhou X, Chen X, Hu DN, Dong XD, Wang J, et al. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci 2009;50:1559-65.
69. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: MiR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle 2007; 6:1586-93. (Pubitemid 47327945)
70. Cole KA, Attiyeh EF, Mosse YP, Laquaglia, MJ, Diskin SJ, Brodeur GM, et al. A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res 2008;6:735-42.
71. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009;69:7569-76.
72. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007;104:15472-7. (Pubitemid 47502941)
73. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009;30:1903-9.
74. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221 and 222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 2009;16:498-509.
75. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008;27:3845-55. (Pubitemid 351862062)
76. Puissegur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-Sermesant K, et al. miR-210 is overexpressed in late stages of lung cancer and mediates mitochondrial alterations associated with modulation of HIF-1 activity. Cell Death Differ 2011;18:465-78.
77. Wang R, Wang ZX, Yang JS, Pan X, De W, Chen LB. MicroRNA-451 functions as a tumor suppressor in human nonsmall cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011;30:2644-58.
78. Voortman J, Goto A, Mendiboure J, Sohn JJ, Schetter AJ, Saito M, et al. MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 2010; 70:8288-98.
79. Duncavage E, Goodgame B, Sezhiyan A, Govindan R, Pfeifer J. Use of microRNA expression levels to predict outcomes in resected stage I non-small cell lung cancer. J Thorac Oncol 2010;5:1755-63.
80. Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, et al. Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010;64:399-408.
81. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
82. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
83. Bishop JA, Benjamin H, Cholakh H, Chajut A, Clark DP, Westra WH. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010;16:610-9.
84. Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol 2009;27:2030-7.
85. Landi MT, Zhao Y, Rotunno M, Koshiol J, Liu H, Bergen AW, et al. MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010;16:430-41.
86. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-9. (Pubitemid 351501813)
87. Du L, Schageman JJ, Irnov Girard L, Hammond SM, Minna JD, Gazdar AF, et al. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs. J Exp Clin Cancer Res 2010;29:75.
88. Del Vescovo V, Cantaloni C, Cucino A, Girlando S, Silvestri M, Bragantini E, et al. miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol 2011;35: 268-75.
89. Axelsen JB, Lotem J, Sachs L, Domany E. Genes overexpressed in different human solid cancers exhibit different tissuespecific expression profiles. Proc Natl Acad Sci USA 2007;104: 13122-7. (Pubitemid 351737603)
90. Ge X, Yamamoto S, Tsutsumi S, Midorikawa Y, Ihara S, Wang SM. et al. Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005;86:127-41. (Pubitemid 40917220)
91. Coulouarn C, Factor VM, Andersen JB, Durkin ME, Thorgeirsson SS. Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene 2009;28:3526-36.
92. Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer 2007; 120:1046-54. (Pubitemid 46214304)
93. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 2008;6:14.
94. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007;8:166.
95. Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res 2007;67:2456-68. (Pubitemid 46548930)
96. Liu X, Sempere LF, Galimberti F, Freemantle SJ, Black C, Dragnev KH, et al. Uncovering growth-suppressive Micro-RNAs in lung cancer. Clin Cancer Res 2009;15:1177-83.
97. Mascaux C, Laes JF, Anthoine G, Haller A, Ninane V, Burny A, et al. Evolution of microRNA expression during human bronchial squamous carcinogenesis. Eur Respir J 2009;33: 352-9.
98. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-4. (Pubitemid 47014436)
99. Liang Y. An expression meta-analysis of predicted microRNA targets identifies a diagnostic signature for lung cancer. BMC Med Genomics 2008;1:61.
100. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 2001;98:13784-9. (Pubitemid 33115976)
101. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5. (Pubitemid 351667616)
102. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumorderived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008;110:13-21. (Pubitemid 351853251)
103. Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer 2010;127:118-26.
104. Kanemaru H, Fukushima S, Yamashita J, Honda N, Oyama R, Kakimoto A, et al. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 2011;61:187-93.
105. Niu Z, Li A, Zhang SX, Schwartz RJ. Serum response factor micromanaging cardiogenesis. Curr Opin Cell Biol 2007;19: 618-27. (Pubitemid 350216421)
106. Niu Z, Iyer D, Conway SJ, Martin JF, Ivey K, Srivastava D, et al. Serum response factor orchestrates nascent sarcomerogenesis and silences the biomineralization gene program in the heart. Proc Natl Acad Sci USA 2008;105:17824-9.
107. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008;3:e3148.
108. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, et al. Serum microRNA signatures identified in a genome-wide serum microRNA xpression profiling predict survival of non-smallcell lung cancer. J Clin Oncol 2010;28:1721-6.
109. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
110. Xie L, Chen X, Wang L, Qian X, Wang T, Wei J, et al. Cellfree miRNAs may indicate diagnosis and docetaxel sensitivity of tumor cells in malignant effusions. BMC Cancer 2010;10: 591.
111. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: Serum-based microRNA biomarkers for early-stage non-small cell lung cancer. J Thorac Oncol 2011;6:482-8.
112. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011;91:579-87.
113. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011;108:3713-8.
114. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009;4:e6229.
115. Silva J, García V, Zaballos A, Provencio M, Lombardía L, Almonacid L, et al. Vesicle-related microRNAs in plasma of nonsmall cell lung cancer patients and correlation with survival. Eur Respir J 2011;37:617-23.
116. Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, et al. Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer 2010;127:2870-8.
117. Cho WC. MicroRNAs as therapeutic targets for lung cancer. Expert Opin Ther Targets 2010;14:1005-8.
118. Heneghan HM, Miller N, Kerin MJ. MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol 2010; 10:543-50.
119. Du L, Pertsemlidis A. microRNAs and lung cancer: Tumors and 22-mers. Cancer Metastasis Rev 2010;29:109-22.
120. Esquela-Kerscher A, Trang P, Wiggins JF, Patrawala L, Cheng A, Ford L, et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle 2008;7:759-64. (Pubitemid 351520040)
121. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, et al. EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 2008;19: 1053-9. (Pubitemid 351796329)
122. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010;70:5923-30.
123. Wu DW, Cheng YW, Wang J, Chen CY, Lee H. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res 2010;70:10392-401.
124. Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A, et al. miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 2010;29:151.
125. Frezzetti D, De Menna M, Zoppoli P, Guerra C, Ferraro A, Bello AM, et al. Upregulation of miR-21 by Ras in vivo and its role in tumor growth. Oncogene 2011;30:275-86.
126. Sethupathy P, Megraw M, Hatzigeorgiou AG. A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 2006;3:881-6. (Pubitemid 44614721)
127. Hayes DN, Monti S, Parmigiani G, Gilks CB, Naoki K, Bhattacharjee A, et al. Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. J Clin Oncol 2006;24:5079-90. (Pubitemid 46631412)
128. Boutros PC, Lau SK, Pintilie M, Liu N, Shepherd FA, Der SD, et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci USA 2009;106:2824-8.
129. Nana-Sinkam SP, Fabbri M, Croce CM. MicroRNAs in cancer: Personalizing diagnosis and therapy. Ann NY Acad Sci 2010;1210:25-33.